Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients

AIDS Research and Human Retroviruses

Volumn 25, Issue 11, 2009, Pages 1179-1185

  Rajesh, Lakshmi ^a   Karunaianantham, Ramesh ^a   Narayanan, Paranji R ^a   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; DIDANOSINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; LAMIVUDINE; MALE; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; TUBERCULOSIS;

EID: 71949094894     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0110     Document Type: Article

References (18)

1. National AIDS Control Organisation (NACO): Antiretroviral therapy guidelines for HIV infected adults and adolescents including postexposure. www.nacoonline.org. Accessed Dec. 2008.
2. Soundararajan L, Karunaianandham R, Jauvin V, et al.: Characterization of HIV-1 isolates from antiretroviral drugnaive children in southern India. AIDS Res Hum Retroviruses 2007;23(9):1119-1126.
3. Balakrishnan P, Kumarasamy N, Kantor R, et al.: HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses 2005;21(4):301-305.
4. Siddappa NB, Dash PK, Mahadevan A, et al.: Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India. J Clin Microbiol 2004;42(6):2742-2751.
5. Shafer RW: Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15(2): 247-277.
6. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, and Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther 2008;13(2):25-36.
7. World Health Organization (WHO): Guidelines for HIV Surveillance among Tuberculosis Patients, 2nd ed. Geneva, Switzerland, 2004.
8. Harries AD, Zachariah R, and Lawn SD: Providing HIV care for co-infected tuberculosis patients: A perspective from sub- Saharan Africa. Int J Tuberc Lung Dis 2009;13(1):6-16.
9. Lall M, Gupta RM, Sen S, Kapila K, Tripathy SP, and Paranjape RS: Profile of primary resistance in HIV-1-infected treatment-naive individuals from western India. AIDS Res Hum Retroviruses 2008;24(7):987-990.
10. Arora SK, Gupta S, Toor JS, and Singla A: Drug resistanceassociated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. AIDS Res Hum Retroviruses 2008;24(2):125-130.
11. Sen S, Tripathy SP, Patil AA, Chimanpure VM, and Paranjape RS: High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007;23(10):1303-1308.
12. Deshpande A, Jauvin V, Magnin N, et al.: Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: Resistance to AR. AIDS Res Hum Retroviruses 2007;23(2):335-340.
13. Ross L, Lim ML, Liao Q, et al.: Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin Trials 2007;8(1):1-8.
14. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192(6):958-966.
15. Jack C, Lalloo U, Karim QA, et al.: A pilot study of oncedaily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004;36(4):929-934. (Pubitemid 38944088)
16. Gupta RK, Chrystie IL, O'Shea S, Mullen JE, Kulasegaram R, and Tong CY: K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 2005; 19(16):1916-1919.
17. Brenner B, Turner D, Oliveira M, et al.: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers crossresistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17(1):F1-5.
18. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al.: Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr 2006;42(1):36-41.